Alseres CEO notes molecular-imaging candidate is in Phase III studies

06/12/2008 | PharmaLive.com

Alseres Pharmaceuticals' lead molecular-imaging candidate, Altropane, is in two-part Phase III clinical trials to test its diagnostic efficacy in Parkinson's disease patients with tremor, according to the company chairman and CEO's annual letter to stockholders.

View Full Article in:

PharmaLive.com

Published in Brief:

SmartBrief Job Listings for Health Care